NICE does not recommend Besponsa (inotuzumab ozogamicin) to treat relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia.- Pfizer
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Pfizer’s Besponsa (inotuzumab ozogamicin) to treat patients with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL).
NICE concludes that evidence from clinical trials showed no survival benefit from Besponsa compared to current treatment, but NICE accepted that more people who were treated with the drug were able to subsequently have a stem cell transplant and go into remission than those on standard care. Because of the “highly uncertain” survival benefits, the incremental cost effectiveness ratio (ICER) was over £100,000 per QALY for Besponsa, which is substantially higher than the range considered cost effective for routine use in the NHS.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins